Tranexamic acid (TXA) proves beneficial in reducing blood loss during various orthopedic procedures. Specifically, consider TXA for total knee arthroplasty (TKA) and total hip arthroplasty (THA) to minimize perioperative blood loss and transfusion requirements. This is particularly relevant for patients at higher risk of bleeding, such as those with a history of anemia or on anticoagulants.
The use of TXA is also supported in other major orthopedic surgeries, including revision arthroplasties, where the risk of significant bleeding is increased due to the complexity of the procedure and potential for vascular injury.
For trauma patients undergoing procedures such as fracture fixation, TXA administration may be considered to manage blood loss and improve outcomes, particularly in cases of significant soft tissue injury or pelvic fractures. However, individual patient risk factors and the severity of the trauma should guide this decision.
Remember to consult current guidelines and clinical trials for specific recommendations tailored to your patient population and procedural context. Careful patient selection is key to maximizing TXA’s benefits and minimizing potential adverse effects.
